secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0001193125-23-258115
Event type: litigation
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos settles Janssen lawsuit; dismisses counterclaims, releases all parties
-----------------------------------------------------------------------------

- Settlement agreement entered Oct 16, 2023 with Janssen Biotech resolving breach of contract and tortious interference claims.
- Janssen dismisses action and releases Aligos, CEO Lawrence Blatt, and President Leonid Beigelman from all claims.
- Aligos dismisses counterclaims for unfair competition and promissory fraud and releases Janssen.
- No admission of liability or financial terms of settlement disclosed in the filing.
- Litigation involved intellectual property ownership and claims against top executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000119312523258115/0001193125-23-258115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000119312523258115/d562095d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-258115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer